Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Sponsor: China Medical University Hospital
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2020-10-13
Completion Date
2026-12
Last Updated
2025-02-19
Healthy Volunteers
No
Conditions
Interventions
NMDAE plus AIFA
Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.
NMDAE plus Placebo Cap
Use of an NMDA enhancer plus placebo as a comparator
Locations (1)
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan